Thomas Pechin, MD
Family Medicine · Shipshewana, INNPI 1982675864
Payments from drug & device makers
Across 125 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$373
- Lilly USA, LLC$202
- Johnson & Johnson$173
- Pfizer$164
- Boehringer Ingelheim$152
- Lundbeck LLC$141
- plus $918 from 29 others
What the payments were for
- Food & beverage$2,08798%
- Education$372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $373 |
| Lilly USA, LLC | 13 | $202 |
| Johnson & Johnson | 12 | $173 |
| Pfizer | 10 | $164 |
| Boehringer Ingelheim | 8 | $152 |
| Lundbeck LLC | 7 | $141 |
| Exact Sciences | 5 | $86 |
| Amgen | 4 | $62 |
| AbbVie | 3 | $57 |
| Abbott | 3 | $56 |
| Genentech USA, Inc. | 3 | $48 |
| Bayer | 3 | $48 |
| Astellas Pharma US Inc | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Vyera Pharmaceuticals, LLC | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 1 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Novartis | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Mylan Specialty L.p. | 1 | $29 |
| Merck | 2 | $27 |
| Seqirus USA Inc | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| CSL Behring | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Radius Health, Inc. | 1 | $11 |
How this compares
$2,124 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 565 | $231,388 |
| XareltoRivaroxaban | 250 | $91,797 |
| MounjaroTirzepatide | 63 | $73,317 |
| JardianceEmpagliflozin | 105 | $65,564 |
| NuplazidPimavanserin Tartrate | 26 | $64,069 |
| TrulicityDulaglutide | 67 | $56,191 |
| OzempicSemaglutide | 44 | $47,619 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $43,089 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $29,310 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 40 | $27,554 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $23,327 |
| Bydureon BciseExenatide Microspheres | 25 | $21,993 |
| Austedo XrDeutetrabenazine | 14 | $20,488 |
| TradjentaLinagliptin | 29 | $18,925 |
| Tetrabenazine | 11 | $17,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $231,388565 claims |
| Lilly USA, LLCMounjaro, Trulicity | $202 | $129,508130 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $152 | $112,043174 claims |
| Johnson & JohnsonXarelto | $173 | $91,797250 claims |
| Acadia Pharmaceuticals IncNuplazid | $18 | $64,06926 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $13 | $59,301105 claims |
| Novo NordiskOzempic | $373 | $47,61944 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $14 | $20,48814 claims |
| NovartisEntresto | $34 | $11,58722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Shipshewana
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.